Navigation Links
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension

wn underlying cause, or it can occur secondary to diseases such as connective tissue disease, congenital heart defects, cirrhosis of the liver and HIV infection. PAH afflicts approximately 200,000 patients worldwide.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to Gilead's ability to successfully commercialize ambrisentan for PAH. For example, the FDA may not approve ambrisentan for the treatment of PAH in the United States, and marketing approval, if granted, may have significant limitations on its use. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. Further, safety and efficacy data from additional clinical studies may not warrant further development of this compound and completing our clinical studies may take longer or cost more than expected. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and its Report on Form 10-Q for the fi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:8/1/2014)... , August 1, 2014 ... by Type (Traditional Wound Closure, Anti infective), Basic (Films, ... Skin & Skin Substitutes), Pressure Relief Devices, NPWT) ... global Wound Care Market is expected to reach ... 2014, growing at a CAGR of 3.2% from ...
(Date:8/1/2014)... Pa. , Aug. 1, 2014 Inovio ... will host a conference call to report its second ... at 9:00 AM ET. CEO Dr. J. Joseph ... discuss second quarter earnings, provide a corporate update, and ... will include clinical development plans for VGX-3100, Inovio,s immune ...
(Date:7/31/2014)... 2014  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
Breaking Medicine Technology:Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/2/2014)... KY (PRWEB) August 02, 2014 ... Lakeview Estates neighborhood on Lexington’s southeast side, has undertaken ... a little better in the “green” sense, while improving ... Brad Rose, Lakewood Park’s property manager, announced that Lakewood ... its tenants. “We’re really excited about being able ...
(Date:8/2/2014)... August 02, 2014 CEDR HR ... number one provider of customized medical and dental employee ... dental-industry conferences this fall. CEDR’s CEO will be featured ... and early December. , From September 4-6, CEDR will ... Managers (AADOM) Dental Managers Conference in San Diego, to ...
(Date:8/1/2014)... (PRWEB) August 02, 2014 The successful ... the stamping business of Guangdong FODAY Automobile Co.,LTD. As ... the company had already organized an excellent team to ... number of detailed, in-depth technical plans. The company’s vice ... were in the direct involvement of the specific arrangement ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... appetite and whole-body metabolism. A protein known as PPARγ ... and body weight, but the identity of the neurons ... new study in the Journal of Clinical Investigation ... neuron known as pro-opiomelanocortin (POMC) neurons is critical in ... and colleagues at Yale University School of Medicine found ...
Breaking Medicine News(10 mins):Health News:Lexington’s Lakewood Park Apartments Getting Into Gardening 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2
... University shows for the first time that the brain ... food and drugs - offering insights into our propensity ... boxing and football. , The research will be published ... Psychopharmacology. , Aggression occurs among virtually all vertebrates and ...
... Routing cue works like a Zip code helps deliver mail, ... researchers have found a way to modify the surface of ... advance that may prove useful in many areas of stem ... at Brigham and Women,s Hospital in Boston modified the surface ...
... $25.5 Million Investment in Detroit - Opens Thursday, DETROIT, ... of Detroit Mercy will be opening a new School of ... giving back to,the City of Detroit. The new wireless facility ... country., Over 261,000 square feet, the School,s new location ...
... Recognising people, objects or animals by the sound they make ... take for granted. But very similar objects can physically make ... subtle clues about the identity and source of the sound. ... (BBSRC) are working out how the human ear and the ...
... into ,skeleton, of animal organ was beating in just ... An organ-building biotechnology that could create transplantable hearts using ... laboratory tests, researchers report. , The technique, called whole ... tissue, according to a report in the Jan. 13 ...
... Fortune 500 Executive Driving Global Breast Cancer Leader,s Promise ... Quickly, End Breast Cancer Forever, ATLANTA, Jan. 12 ... Cure, the global leader in the fight to end breast,cancer ... the,16th annual Trumpet Awards event in Atlanta with a ,High ...
Cached Medicine News:Health News:Aggression as rewarding as sex, food and drugs 2Health News:Stem Cells Modified to Home in Where They're Needed 2Health News:University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 2Health News:University of Detroit Mercy School of Dentistry Moves to Larger Facility on New Corktown Campus 3Health News:Lend me your ears -- and the world will sound very different 2Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3
Head-worn Loupe G3, Galilean teleloupe system....
... The XL Advantage delivers higher magnification for ... crisp, true image, even at the highest ... edge clarity and precise color rendition is ... with an anti-reflective coating produce a superior ...
... The XL Advantage delivers higher magnification ... a crisp, true image, even at the ... to edge clarity and precise color rendition ... treated with an anti-reflective coating produce a ...
... higher magnification for advanced surgical procedures. Prismatic ... at the highest magnification. 3.5x, 4.5x and ... color rendition is ideal for surgical applications. ... produce a superior image. The compact abd ...
Medicine Products: